Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
НЦПЗ РАМН, Москва
Список исп. литературыСкрыть список 1. Cannon TD, van Erp ThGM, Bearden CE et al. Early and late neurodevelopmental influences in the prodrome to shizophrenia: contributions of genes, enviroment and their interactions. Schizophr Bull 2003; 29 (4): 653–69. 2. Clarke MC, Harley M, Cannon M. The role of obstetric events in shizophrenia. Schizophr Bull 2006; 32 (1): 3–8. 3. Cornblatt BA. The schizophrenia prodrome: promise for intervention. Dialog Clin Neuroscience 2001; 3 (1): 93–8. 4. Cornblatt BA, Lencz T, Smith ChrW et al. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bulletin 2003; 29 (4): 633–51. 5. Cornblatt BA. Are antidepressants an alternative for the early treatment of the schizophrenia prodrome? 160th Annual meeting, San Diego, California, may 19–24, 2007. Proceeding Summary. 2007; p. 206. 6. Hultman ChrM, Ohman A, Chattinguis S et al. Prenatal and neonatal risk factors for schizophrenia. Br J Psychiat 1997; 170: 128–33. 7. Jaaskelainen E, Miettunen J, Veijola J et al. Associations between early development and outcome in schizophrenia – A 35-year follow-up of the Nothern Finland 1966 birth cohort. Schizophr. Research 2008; 99: 29–37. 8. Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders. Implications for prevention. Aust NZJ Psychiat 2000; 34 (Suppl.): S26–34. 9. Klosterkotter J, Bechdorf A, Ruhrmann S. Early intervention in the initial prodromal phase: results from the German research network on schizophrenia. 160th Annual meeting, San Diego, California, may 19–24, 2007. Proceeding Summary. 2007; p. 206. 10. Lapin JM. Gray matter abnormalities associated with duration of untreated psychosis. Schizophr Res 2006; 83: 145–53. 11. Lieberman AJ, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology and therapeutic approaches. Biol Psychiatry 2001; 50: 884–97. 12. Maier W, Cornblatt BA, Merikangas KR. Transition to schizophrenia and related disorders: toward a taxonomy of risk. Schizophr Bull 2003; 29 (4): 693–701. 13. McGlashan TH, Zipursky RP, Perkins D et al. Randomized double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiat 2006; 163: 790–9. 14. McGlashan ThH. Treating subsyndromal schizophrenia: why the uproar? 160th Annual meeting, San Diego, California, may 19–24, 2007. Proceeding Summary. 2007; p. 187–8. 15. McGrath. Universal interventions for primary prevention of schizophrenia. Aust NZJ Psychiat 2000; 34 (Suppl.): S58–64. 16. McGorry PD, Edwards J, Mihalopoulus C et al. EPPIC – an evolving system of early detection and optimal management. Schizophr Bull 1996; 22: 305–26. 17. McGorry PD, Yung AR, Phillips LG et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with substhreshold symptoms. Arch Gen Psychiat 2002; 59: 921–8. 18. Miller TJ. Prodromal assesment with the structured interview for prodromal syndroms and the scale of prodromal symptoms: predictive validity, interrater reliability and training reliability. Schizophr Bull 2003; 29 (4): 703–15. 19. Mojtabai R, Malaspina D, Susser E. The concept of population prevention: application to schizophrenia. Schizophr Bull 2003; 29 (4): 791–801. 20. Moller P, Husby R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr Bull 2000; 26 (1): 217–32. 21. Morrison AP, French P, Walford L et al. Cognitive Therapy for the prevention of psychosis in people at ultra-high risk: randomized controlled trial. Br J Psychiat 2004; 185: 291–7. 22. Murray GK, Jones PB, Moilanen K et al. Infant motor development and adult cognitive functions in schizophrenia. Schizophr Res 2006; 81: 65–74. 23. Parker S, Lewis S. Identification of young people at risk of psychosis. Advan Psychiatry Treatment 2006; 12: 249–55. 24. Phillips LJ, Yung AR, Hearn N et al. Preventive mental health care: accessing the target population. Aust NZJ Psychiat 1999; 33: 912–7. 25. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust NZJ Psychiat 2000; 34: S164–9. 26. Pukrop R, Ruhrmann S, Schultz-Lutter F et al. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res 2007; 92: 116–25. 27. Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkotter J. Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiat 2005; 20: 1–6. 28. Simon AE., Ferrero FP, Merio M. Prodromes of first-episode psychosis: how can we challenge nonspecifity? Comp Psychiat 2001; 42 (5): 382–92. 29. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Canadian J Psychiat 2002; 47: 521–6. 30. Warner R. The prevention of schizophrenia: what interventions are safe and effective. Schizophr Bull 2001; 27 (4): 551–61. 31. Woods BT. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenic mechanism. Am J Psychist 1998; 155 (12): 1661–70. 32. Yung AR, Phillips LJ, Yuen HP. Psychosis prediction: 12-month follow-up of a high-risk («prodromal») group. Schizoph Res 2003; 60: 21–32. 33. Yung AR, Phillips LJ, Yuen HP et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131–42. 34. Yung AR, Nelson B, Stanford C et al. Validation of «prodromal» criteria to detect individuals at ultra high-risk of psychosis: 2 year follow-up. Schizophr Research 2008; 105: 10–7.